Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
115.25 USD | +0.47% | -2.82% | +5.71% |
12/09 | Merck Says Health Canada Approved Keytruda as Treatment for Hard-to-Treat Solid Tumors | MT |
11/09 | Merck: positive results for HPV vaccine | CF |
Analyst Opinion | 4m Target Price Revision | 4m Revision of opinion | Divergence of analysts' opinions | Divergence of Target Price | Average Target P. | Ecart obj. / dr | Nbr of analysts | ||
---|---|---|---|---|---|---|---|---|---|
139.03 | +21.20% | 26 | |||||||
986.82 | +7.16% | 25 | |||||||
967.54 | +8.65% | 26 | |||||||
170.67 | +3.55% | 22 | |||||||
196.30 | +0.88% | 27 | |||||||
298.00 | +10.86% | 19 | |||||||
184.19 | +14.91% | 20 | |||||||
116.54 | +1.49% | 20 | |||||||
324.71 | -1.60% | 24 | |||||||
33.23 | +12.05% | 22 | |||||||
111.95 | +7.07% | 22 | |||||||
83.54 | +3.21% | 27 | |||||||
53.34 | +9.77% | 21 | |||||||
19.68 | +18.94% | 21 | |||||||
6,663.33 | +2.83% | 15 | |||||||
6,531.25 | +25.58% | 16 | |||||||
4,768.83 | +13.68% | 18 | |||||||
3.842 | -2.49% | 17 | |||||||
58.20 | +28.10% | 15 | |||||||
Average | 1,142.68 | +9.78% | 21 | ||||||
Weighted average by Cap. | 711.2 | +8.25% | 23 |
- Stock Market
- Equities
- MRK Stock
- Sector Merck & Co., Inc.
- Sector consensus
MarketScreener is also available in this country: United States.
Switch edition